Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain
Under a Creative Commons license
open access
Keywords
Breast neoplasms
Healthcare costs
Poly(ADP-Ribose) polymerase inhibitors
Cost-utility analysis
Progression-free survival
Cited by (0)
© 2021 The Authors. Published by Elsevier Ltd.